Compare RLMD & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLMD | NPCE |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 777.2M | 623.0M |
| IPO Year | 2012 | 2021 |
| Metric | RLMD | NPCE |
|---|---|---|
| Price | $7.40 | $15.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $12.40 | ★ $18.33 |
| AVG Volume (30 Days) | ★ 1.1M | 172.2K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | 29.03 |
| EPS | N/A | ★ N/A |
| Revenue | $13,070.00 | ★ $99,986,000.00 |
| Revenue This Year | N/A | $0.90 |
| Revenue Next Year | N/A | $24.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 154.83 | 25.13 |
| 52 Week Low | $0.44 | $7.56 |
| 52 Week High | $8.00 | $19.60 |
| Indicator | RLMD | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 46.18 |
| Support Level | $6.81 | $15.17 |
| Resistance Level | $7.94 | $16.65 |
| Average True Range (ATR) | 0.42 | 1.06 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 51.79 | 20.04 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.